Antonio Jimenez, MD, Sylvester Comprehensive Cancer Center, Miami Springs, FL, discusses a study aiming to evaluate the prognostic ability of a modified European LeukemiaNet (mELN) classification system based on available Center for International Blood and Marrow Transplant Research (CIBMTR) data, to predict post-transplant outcomes in acute myeloid leukemia (AML) patients. Over two thousand AML patients in their first remission were initially stratified into three groups: favorable (Fav), intermediate (IM), and adverse (Adv). While significant differences were found among the groups in terms of relapse, disease-free survival, and overall survival, the results for the Fav and IM groups were comparable and the stratification was ultimately changed to two groups: favorable and unfavorable. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
